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Background: The purpose of our study was to investigate the potential contribution of germline mutations in
NOTCH1, GATA5 and TGFBR1 and TGFBR2 genes in a cohort of Italian patients with familial Bicuspid Aortic Valve
(BAV).
Methods: All the coding exons including adjacent intronic as well as 50 and 30 untranslated (UTR) sequences of
NOTCH1, GATA5, TGFBR1 and TGFBR2 genes were screened by direct gene sequencing in 11 index patients (8 males;
age = 42 ± 19 years) with familial BAV defined as two or more affected members.
Results: Two novel mutations, a missense and a nonsense mutation (Exon 5, p.P284L; Exon 26, p.Y1619X), were
found in the NOTCH1 gene in two unrelated families. The mutations segregated with the disease in these families,
and they were not found on 200 unrelated chromosomes from ethnically matched controls. No pathogenetic
mutation was identified in GATA5, TGFBR1 and TGFBR2 genes.
Conclusions: Two novel NOTCH1 mutations were identified in two Italian families with BAV, highlighting the role of
a NOTCH1 signaling pathway in BAV and its aortic complications. These findings are of relevance for genetic
counseling and clinical care of families presenting with BAV. Future studies are needed in order to unravel the still
largely unknown genetics of BAV.
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Bicuspid aortic valve (BAV) is the most common con-
genital cardiac malformation, with a prevalence esti-
mated between 0.5% and 2% [1,2]. Nearly all patients
with BAV develop serious aortic complications, includ-
ing significant valve regurgitation, severe aortic stenosis,
aortic aneurysm and dissection [3,4]. Therefore, the bur-
den of BAV disease is more significant than any other
congenital cardiac abnormalities [4]. Clinical studies
have reported high heritability in families of patients
with BAV [5-7], suggesting a Mendelian pattern of in-
heritance and the need for echocardiography screening
in first-degree relatives of patients with BAV [8].* Correspondence: andreassi@ifc.cnr.it
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reproduction in any medium, provided the orA family-based linkage analysis has identified genomic
regions on chromosomes 18q, 5q and 13q responsible
for BAV and associated cardiac malformations, but the
precise genes within these regions were not defined [9].
To date, only mutations in the NOTCH1 gene, a sig-
naling transmembrane receptor (2,556 amino acids) in-
volved in multiple cell aspects of vascular development,
have been associated with dominantly inherited BAV in
a small number of families [10].
However, the rate of NOTCH1 gene mutations in fa-
milial forms of BAV and their association with different
clinical complications remains incomplete [11,12]. Inter-
estingly, McBride et al. demonstrated that mutations in
the gene NOTCH1 are found in cases of left ventricular
outflow tract (LVOT) malformations including aortic
valve stenosis, coarctation of the aorta and hypoplastic
left heart syndrome [13]. In particular, a much higherd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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families with LVOT malformations compared to the
general population, suggesting that BAV may be a forme
frusta of the more serious LVOT malformations [13].
Recently, a missense mutation in transforming growth
factor-beta receptor 2 gene (TGFBR2) was found in a pa-
tient with BAV and aortic aneurysm [14], but earlier
studies found no mutation in either TGFBR1 or TGFBR2
in patients with familial and sporadic BAV disease
[15,16].
Finally, GATA5 was reported to have an essential role
in cardiac morphogenesis and in aortic valve develop-
ment [17,18], and targeted deletion of this gene in mice
leads to partially penetrant BAV [19]. Accordingly, a very
recent study investigated the relationship between
GATA5 gene variations and BAV disease identifying rare
non-synonymous variations in the functionally impor-
tant GATA5 transcriptional activation domain [20]. Con-
versely from NOTCH1 gene, the involvement of GATA5
has not been described in other LVOT malformations.
However, further studies are needed to assess the in-
volvement of NOTCH1, GATA5 and TGFBR1 andA B C
GF
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Figure 1 Pedigrees of BAV families A-K. The proband is indicated by arr
represent deceased individuals.TGFBR2 mutations in patients with BAV and its associ-
ated aortic complications.
The purpose of our study was to investigate the poten-
tial contribution of germline mutations in NOTCH1,
GATA5, TGFBR1 and TGFBR2 genes in a cohort of Ital-
ian patients with familial BAV.
Methods
Study population
A cohort of 11 unrelated Italian patients (8 males; age =
42 ± 19 years) with familial BAV were recruited for this
study. Patients with sporadic BAV and/or with coexisting
syndromes, such as Marfan syndrome, Turner syndrome
and Di George syndrome or unknown syndromes were
excluded from the study. Clinical evaluation consisted of
medical history, physical examination, 2-dimensional
echocardiography and a complete Magnetic Resonance
Imaging (MRI) study. A detailed family history was
obtained for each proband. Familial BAV was defined if
two or more affected relatives had proven BAV diagnosed
by echocardiography or cardiac magnetic resonance.
Figure 1 shows the pedigree of BAV patients. Patient’sD E
H
K
ow and affected status is indicated by filled symbol. Slanted bars
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(18%) had BAV with unknown morphology. Of the 9 pro-
bands with known BAV morphology, 7 (63%) had fusion
of the right/left coronary commissure whereas 2 (18%)
had a valve with anterior-posterior sinus without raphe.
We also included a control cohort comprised of 100 eth-
nically unrelated individuals (60 male; age = 35 ± 16 years)
without BAV as shown by echocardiography. This study
was conducted with informed consent of every partici-
pant subject and was approved by the local Ethical Re-
search Committee.
Mutational sequencing analysis
A mutational screening was performed by direct gene
sequencing of all coding exons including adjacent in-
tronic as well as 50 and 30 untranslated sequences of
NOTCH1, GATA5 and TGFBR1, TGFBR2 genes. Gen-
omic DNA was extracted from peripheral blood cells
using the QIAGEN BioRobotW EZ1 System. Exons and
the flanking intronic sequences were amplified by poly-
merase chain reaction (PCR) using specific primers as
described previously for NOTCH1 and TGFBR1 and
TGFBR2 [11,21] and using Primer3 (v. 0.4.0) software
(http://frodo.wi.mit.edu/primer3/) based on the cDNA
sequences available in GenBank for GATA5 screening.
Approximately, PCR amplifications were performed
with a volume of 50 microl mixture containing 1.5 mM
MgCl2, 10 mMdNTP, 50 ng genomic DNA, 20 micromol
of each primer and 2.5 U Taq DNA polymerase. PCR
product was used for PCR sequencing reaction with the
CEQ DTCS Quick Start Kit. The sequencing reaction
products were purified by precipitation with ethanol,
re-suspended in a sample loading solution and analyzed
with a CEQ 8800 capillary sequence (Beckman Coulter,
Germany) according to the manufacturer’s protocol.
Resulting sequences were analyzed using CEQ 8800Table 1 Clinical and demographic characteristics of study pop
Proband Sex Age Diagnosis
A M 40 AS and AAD
B M 25 AR and AAD
C F 40 AR
D F 21 AR
E M 37 BAV
F M 74 AS and AAD
G M 17 AI and AAD
H M 67 AR and AAD
I M 38 AS
J F 65 AS and AAD
K M 37 AR and AAD
AS: aortic stenosis; AAD: Ascending Aortic Dilation; AR: Aortic regurgitation; AI: aort
right/left coronary commissure; unk: unknown.software packages and aligned against a reference se-
quence obtained from GenBank.
For prediction of the functional consequences of mu-
tations on protein sequence, we used software pro-
grams available on the internet, namely PolyPhen-2
(http://genetics.bwh.harvard.edu/pph/) SIFT (http://sift.
jcvi.org/) and Mutation Taster (www.mutationtaster.
org/). PolyPhen-2 predicts the effect of an amino acid
substitution on the structure and function of a protein,
using sequence homology. The PolyPhen-2 score rep-
resents the probability that a substitution is damaging,
so values nearer 1 are more confidently predicted to
be deleterious (note that this is the opposite of SIFT).
SIFT uses sequence homology to predict whether an
amino acid substitution will affect the protein function.
SIFT score <0.05 indicates the amino acid substitution is
damaging while scores ≥ 0.05 are predicted to be tole-
rant. Mutation Taster is a free, web-based application
for rapid evaluation of the disease-causing potential of
DNA sequence alterations. Mutation Taster integrates
information from different biomedical databases and
uses established analysis tools. Analyses comprise evo-
lutionary conservation, splice-site changes, loss of pro-
tein features and changes that might affect the amount of
mRNA.
Detected mutations in probands were confirmed by se-
quencing in the opposite direction from another two in-
dependent PCR products.
The presence of a novel mutation was assessed in 200
ethnically reference alleles derived from volunteers by
PCR-based restriction fragment length polymorphism
(PCR-RFLP) or by direct gene sequencing.
Results
Clinical and demographic characteristics of each patient
are summarized in Table 1. The group comprised 73%ulation
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cardiovascular anomalies occurred in 18% of the cohort.
Genetic analysis of NOTCH1 gene
A mutational screening was performed by direct gene
sequencing of all 34 coding exons including adjacent in-
tronic as well as 50 and 30 untranslated sequences of
NOTCH1 gene. Seventeen separate NOTCH1 sequence
variants listed previously in public dbSNPs or in the litera-
ture were found in our patients, while five variants were
novel. These included one synonymous variant (Exon 21,
p.G1166G), two intronic (IVS11 + 63; IVS32-41) and two
novel mutations (Exon 5,p.P284L; Exon 26, p.Y1619X).
Details of the specific sequence variants and number of
positive patients are summarized in Table 2.
The novel C > T heterozygous substitution in exon 5,
resulting in the substitution of a Proline with a Leucine
(P284L) at position 284, was found in the sequencing
electropherograms of a 40-year-old male patient (Pro-
band A; Figure 2). The identified missense mutation was







g.26979 T > C Exon 3 c.312 T >
g.31330 C > T Exon 5 c.851C >
g.31331 G > A Exon 5 c.852 G >
g.34650 T > C IVS 9-43
g.33525A > G IVS 9 + 10
g.33601 C > A/T IVS 9 + 86
g.33617C > T IVS 9 + 102
g.33620C > T IVS 9 + 105
g.34772C > T Exon 10 c.1635 C >
g.35062A > G IVS 11-9
g.35367 G > A IVS 11 + 63
g.35591C > T IVS 12 + 94
g.36347G > A IVS 13 + 70
g.37307 T > C Exon 14 c.2265 T >
g.39978G > A IVS 16-4
g.40058C > T Exon 17 c.2664 C >
g.40085C > T Exon 17 c.2691 C >
g.42820 C > T Exon 21 c.3498 C >
g.45953 C > G Exon 26 c.4856 C >
g.47532C > T Exon 27 c.5094 C >
g.48831 T > C IVS 30-43
g.49928C > T IVS 30-12
g.51487 C > T IVS 32-41volunteers. PolyPhen-2 analysis predicted the p.P284L
mutation as probably damaging with a score of 0.993.
This result was confirmed by SIFT (score: 0.04).
The missense mutation (p.P284L) identified in our
proband, tested by Mutation Taster, induced the loss of
an important residue with putative significance for cal-
cium binding to epidermal growth factor (EGF)-like 7
domain.
The proband, at the age of 39 years, presented severe
calcified aortic valve and normal diameter of ascending
aorta (39 mm). One year later, the patient underwent
elective aortic valve and ascending aorta repair (48 mm)
replacement. Family history and echocardiography ana-
lysis revealed the presence of BAV in his 7-year-old son.
Genetic screening of the proband’s child confirmed the
presence of p.P284L mutation in exon 5 of NOTCH1
gene.
Moreover, we detected a novel heterozygous C-to-G
transition, in exon 26, of nucleotide 4856 leading to a
premature stop codon at position 1619 (p.Y1619X) in-
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Figure 2 DNA sequencing electropherograms demonstrating the NOTCH1 heterozygous sequence mutations (Exon 5, p.P284L and
Exon 26, p.Y1619X).
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identified mutation was absent in 200 ethnically refer-
ence alleles derived from volunteers. At age 6 months
the proband had surgery to correct the CoA, while at
age 25 years he underwent elective aortic valveTable 3 Genetic variants within the human GATA5 gene ident
Position GATA5 gene HGVS names Protein positi
Exon1 c.199 A > C p.Thr67Pro
Exon 2 c.609 C > T p.Asp203Asp
Exon 2 c.678 C > T p.Leu226Leu
IVS 4-14 c.826-14 G > A
Exon 4 c.852 G > A p.Lys284Lys
IVS 5-16 c.914-16 C > T
Exon 5 c.981 G > C p.Ser327Ser
IVS 6-78 c.1039-78 C > G
Exon6 c.1128 A > G p.Pro376Pro
NM_080473.4.replacement. Family history and echocardiography ana-
lysis revealed the presence of BAV in his 5-year-old
daughter. Genetic screening of the proband’s child
confirmed the presence of p.Y1619X mutation in exon
26 of NOTCH1 gene.ified in familial BAV patients
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Sequencing of all 6 exons and splice signal sequences of
GATA5 in our cohort revealed five synonymous, one
non-synonymous and three intronic variants. Details of
the specific sequence variants and number of positive
patients are summarized in Table 3. We identified one
novel intronic variant (C > T; IVS 5–15) in one patient,
but it was also present in our control group.Genetic analysis of TGFBR1 and TGFBR2 genes
TGFBR1 and TGFBR2 genes were analyzed by direct
gene sequencing of all coding exons including adjacent
intronic as well as 50 and 30 untranslated sequences. No
pathogenetic mutation was identified; we found only
known common genetic polymorphisms. Details of the
specific sequence variants in TGFBR1 and TGFBR2
genes are summarized in Table 4.Discussion
In our cohort of 11 familial patients with BAV two novel
mutations were found in the NOTCH1 gene in two un-
related families. The mutations segregated with the dis-
ease in these families, and they were not found in 200
chromosomes from ethnically matched controls.
On the contrary, analysis of GATA5, TGFBR1 and
TGFBR2 genes identified only known genetic variants.
Our findings confirm the important role of NOTCH1 as
conserved intracellular regulator in the pathogenesis of
congenital valve disease and in its complications. Indeed,
the finding of two independent de novo mutations in this
gene in a small number of affected subjects is compel-
ling evidence of disease causation.
NOTCH1 encodes for a transmembrane protein that
activates a signaling pathway with a major role in cardiac
embryogenesis, including aortic and pulmonary valve de-
velopment as well as the development and maintenance
of the aorta and other great vessels [22]. Murine model
studies indicate that Notch signaling promotes the
epithelial-to mesenchyme transition that gives rise to the
primordial cardiac valve, which later is sculpted into ma-
ture valves [23]. Moreover, a recent study showed that
heterozygous Notch1-null (Notch1(+/)(−) mice hadTable 4 Genetic variants within the human TGFBR1 and TGFB
Gene Position TGFBR1 TGFBR2 gene HGVS names
TGFBR1 Exon 1 c.68_76delCGGCGGCG
IVS 7 + 24 c.1255 + 24 G > A
TGFBR2 IVS 3 + 7 c.338 + 7 A > G
IVS 5-4 c.455-4 T > A
Exon 4 c.458delA
TGFBR1: NM_004612.2 NG_007461.1.
TGFBR2: NM_001024847.2 NG_007490.1.greater than fivefold more aortic valve calcification than
age- and sex-matched wild type littermates [24].
Indeed, in vitro studies showed that Notch1 signaling
repressed valvular Bmp2 expression, and de-repression
of Bmp2 was involved in calcification induced by Notch1
inhibition. Thus, Notch1 signaling appears to prevent
aortic valve calcification in part by repressing Bmp2 ex-
pression within the valve [24].
Defective NOTCH signaling might also contribute to
aortic valve calcification by repressing the activity of the
hairy-related family of transcription factors (Hrt), and
thereby also repressing the Runx2/Cbfa1 pathway, a cen-
tral transcriptional regulator of osteoblast cell fate
[24,25].
In addition, there is increasing evidence of interaction
between the Notch1 pathway and transforming growth
factor beta (TGFβ) [26]. This is particularly important in
light of evidence showing that TGFβ plays an important
role in vascular remodeling and alterations in TGFβ
signaling activity might enhance matrix degradation
[27,28].
In 2005, the discovery of a nonsense (p.R1108X) and a
frameshift mutation (p.H1505del) in two families repre-
sented the first demonstration of NOTCH1 germline
mutations as a cause of BAV and severe valve calcifi-
cation in non-syndromic autosomal-dominant human
pedigrees [10].
Subsequently, two novel mutations (p.T596M and p.
P1797H) located in highly conserved regions of the pro-
tein were identified in patients with sporadic BAV, pro-
viding evidence that mutations in NOTCH1 do not only
play a role in familial BAV, but can also be observed in
approximately 4% of sporadic cases [11]. Furthermore, a
targeted mutational analysis of NOTCH1 demonstrated
the presence of two novel mutations (p.A1343V and p.
P1390T) among patients with BAV with sporadic and
concomitant thoracic aortic aneurysms, providing evi-
dence that mutations in NOTCH1 may also confer sus-
ceptibility to aortic aneurysm formation [12].
In a very recent paper, Kent et al. suggested a
NOTCH1-dependent mechanism that produces stenotic,
insufficient and/or calcified aortic valves with a rare
aneurysm, and a NOTCH1-independent mechanism thatR2 genes identified in familial BAV patients
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(AscAA) in the presence of a non-calcified and often
normally functioning BAV [29]. Our data appear to
agree with and fit well into the proposal made in this
article by Kent et al., since we found two novel muta-
tions in these patients with valve malformation, calcifica-
tion, and dysfunction as predominant phenotype caused
by altered NOTCH1 signaling.
Conversely, we did not identify any pathogenetic mu-
tations in GATA5. The non-synonymous variant
Thr67Pro located in the transcriptional activator domain
encoded by exon 1, detected with a frequency of 45% in
our population, is a common genetic polymorphism pre-
viously described [20,30].
Regarding to TGFBR1 and TGFBR2 genes, in contrast
with a recent paper showing a missense mutation in
TGFBR2 gene in a patient with BAV and aortic
aneurysm [14], our findings support the studies
suggesting that mutations in these genes are rarely iden-
tified in patients with familial BAV [15,16].Conclusion
Although the small number of patients (11) might be an
important study limitation, we have identified two novel
NOTCH1 mutations in two Italian families with BAV.
Our findings confirm the critical role of NOCTH1 in the
development of aortic valve and aortic complications.
Genetic screening for NOTCH1 mutation may be con-
sidered for diagnosis and family screening as part of the
standard management of patients with family history of
BAV. However, the etiology of this common valve dis-
ease is largely unknown. Future studies based on new
genetic screening strategies, the so-called next-
generation sequencing, are needed in order to unravel
the still largely unknown genetics of BAV.
Abbreviations: BAV= Bicuspid Aortic Valve, TGFBR1 =
transforming growth factor-beta receptorI gene; TGFBR2 =
transforming growth factor-beta receptorII gene; PCR-
RFLP = PCR-based restriction fragment length polymorph-
ism; MAF =minor allele frequency; CoA = coarctation of
the aorta; TGFβ = transforming growth factor beta; MRI =
Magnetic Resonance Imaging; AscAA= ascending aortic
aneurysm; LVOT= left ventricular outflow tract.Competing interests
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